“The emerging role of capivasertib in breast cancer”

Over 50% of breast tumors harbor alterations in one or more genes of the phosphatidylinositol 3-kinase (PI3K) pathway including PIK3CA mutations (31%), PTEN loss (34%), PTEN mutations (5%) and AKT1 mutations (3%). While PI3K and mTOR inhibitors are already approved in advanced breast cancer, AKT inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrikopoulou, Angeliki, Chatzinikolaou, Spyridoula, Panourgias, Evangelia, Kaparelou, Maria, Liontos, Michalis, Dimopoulos, Meletios-Athanasios, Zagouri, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011110/
https://www.ncbi.nlm.nih.gov/pubmed/35398754
http://dx.doi.org/10.1016/j.breast.2022.03.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011110/
https://www.ncbi.nlm.nih.gov/pubmed/35398754
http://dx.doi.org/10.1016/j.breast.2022.03.018

Ejemplares similares